Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 6/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6409268 | 0.99 | ROCK2 (0.45) | ROCK2ROCK1CCR5UTS2RLIPG | |
| SCHEMBL6409997 | 0.93 | ROCK2 (0.50) | ROCK2ROCK1CCR5UTS2R | |
| Hydrochloric Acid SCHEMBL6415177 | 0.92 | ROCK2 (0.49) | ROCK2ROCK1CCR5UTS2R | |
| SCHEMBL6412955 | 0.91 | UTS2R (0.53) | ROCK2ROCK1CCR5UTS2R | |
| SCHEMBL6410591 | 0.91 | ROCK2 (0.49) | ROCK2ROCK1CCR5UTS2RMAPT | |
| SCHEMBL6418297 | 0.91 | UTS2R (0.49) | ROCK2ROCK1CCR5UTS2R | |
| SCHEMBL6415211 | 0.91 | ROCK2 (0.46) | ROCK2ROCK1CCR5UTS2RMAPT | |
| SCHEMBL6414689 | 0.91 | UTS2R (0.47) | ROCK2ROCK1CCR5UTS2R | |
| Hydrochloric Acid SCHEMBL6412334 | 0.91 | ROCK2 (0.49) | ROCK2ROCK1CCR5UTS2RMAPT | |
| Hydrochloric Acid SCHEMBL6409513 | 0.91 | UTS2R (0.52) | ROCK2ROCK1CCR5UTS2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776362-A1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | Virochem Pharma Inc. (CA) | 2007-04-25 | — | — | EP | claimed |
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
| WO-2005007656-A1 | SPIRO COMPOUNDS AND METHODS FOR THE MODULATION OF CHEMOKINE RECEPTOR ACTIVITY | VIROCHEM PHARMA INC. (CA) | 2005-01-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | ROCK2 1735/4885ROCK1 1002/4885CCR5 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.